CytoSorbents CTSO 深 沪
等待开盘 08-04 09:30:00 美东时间
0.8692
+0.019
+2.26%
华盛通- 最 高0.8888
- 今 开0.8722
- 成交量 463.42万股
- 最 低 0.7724
- 昨 收 0.85
- 总市值 5442.10万
- 52周最高 1.61
- 市盈率 静 --
- 换手率 7.40%
- 52周最低 0.7101
- 委 比 93.58%
- 总股本 6261.04万
- 历史最高 15.24
- 量 比 50.43
- 振 幅 13.69%
- 历史最低 0.70
- 每 手 1
- 风险率 0.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多A Glimpse Into The Expert Outlook On CytoSorbents Through 5 Analysts
5 analysts have expressed a variety of opinions on CytoSorbents (NASDAQ:CTSO) o...
07-22 06:01
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR
PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and...
07-02 19:00
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
Deep Dive Into CytoSorbents Stock: Analyst Perspectives (6 Ratings)
Ratings for CytoSorbents (NASDAQ:CTSO) were provided by 6 analysts in the past ...
06-25 21:00
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.
06-25 20:41
CytoSorbents Files Request For Supervisory Review With FDA Of De Novo Denial Letter Issued For CytoSorbents' DrugSorb-ATR Device
CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it
06-24 19:10
CytoSorbents Confirms Director Elections at Annual Meeting
Cytosorbents ( ($CTSO) ) just unveiled an announcement. CytoSorbents Corporatio...
06-14 05:49
昊华科技:公司研发和生产实力雄厚,研发的民用航空轮胎具有自主知识产权,技术性能达...
有投资者在上证互动平台向昊华科技提问："您好！请问贵公司是否有特种轮胎（如飞机轮胎）业务？"公司回复称："尊敬的投资者您好，感谢您对公司的关心和支持！昊华科技所...
06-09 15:41
CytoSorbents Presents Real-World Analysis At EuroPCR 2025 Showing Reduction In Severe Bleeding And Transfusion Needs In CABG Patients On Blood Thinner, Ticagrelor, With CytoSorbents Therapy
Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents TherapyPRINCETON, N.J., May 22, 2025
05-22 21:34
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
